Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Tu Hu
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
ORCID:
0000-0002-2779-2672
Observed ORCID:
0000-0002-2779-2672
OpenAlex ID:
A5101559051
The Role of CDCA2 in tumor genesis, prognosis and future treatments
2024
·
Xinyi Lin
, Zijian Zou
, et al.
·
European Journal of Cancer
·
12
PDF
The combination of apatinib and antigen-specific DC-induced T cells exert antitumor effects by potently improving the immune microenvironment of osteosarcoma
2024
·
Tu Hu
, Wei Sun
, et al.
·
Heliyon
·
5
The single cell transcriptomic landscape of recurrent giant cell tumor of bone following neoadjuvant denosumab therapy
2026
·
Xianglin Hu
, Huajian Wu
, et al.
·
Journal of genetics and genomics/Journal of Genetics and Genomics
·
1
The efficacy and safety of neoadjuvant toripalimab combined with temozolomide in resectable stage III melanoma: A prospective, single-center, phase 2 trial.
2026
·
Tu Hu
, Guanxiong Zhang
, et al.
·
Journal of Clinical Oncology
PDF
Neoadjuvant pegylated liposomal doxorubicin plus anlotinib in locally advanced soft tissue sarcoma: Clinical outcomes and multi-omics analysis from a phase II study.
2026
·
Wei Sun
, Zijian Zou
, et al.
·
Journal of Clinical Oncology
PDF
Prognostic value of the number of biopsied sentinel lymph nodes for Chinese patients with melanoma: A single‐center retrospective study
2023
·
Tu Hu
, Yu Xu
, et al.
·
Cancer Reports
PDF
Show more works
View as search
Works count:
6
Citation count:
18
H-index:
2
I10-index:
1
Year
Topic
Type